Opportunity Information: Apply for RFA RM 18 033
The National Institutes of Health (NIH) posted this funding opportunity, RFA-RM-18-033, titled "Multisite Clinical Center Common Fund Acute to Chronic Pain Signatures Program: Acute Pain from Musculoskeletal Trauma (UM1 Clinical Trial Optional)." It is a discretionary federal grant mechanism using a cooperative agreement (UM1), which means the awardee would carry out the work in close coordination with NIH program staff rather than operating entirely independently. The overall aim is to support a single Multisite Clinical Center (MCC) that can recruit and follow a large group of patients who have acute pain due to musculoskeletal trauma, then conduct multimodal and longitudinal assessments to identify biological signatures (biosignatures) linked either to resilience (recovering without developing long-term pain) or to the transition from acute pain to chronic pain.
In practical terms, the opportunity is focused on building a well-characterized cohort soon after an injury and tracking participants over time with multiple types of measurements. "Multimodal longitudinal assessment" signals that the MCC would not rely on one data stream (like surveys alone), but would likely integrate several categories of information collected at multiple timepoints, such as clinical evaluations, patient-reported outcomes, functional measures, and biological or other objective data types intended to support biosignature discovery. The end goal is to understand why some people recover while others go on to develop persistent pain after musculoskeletal trauma, and to generate evidence that can support better prediction, prevention, or targeted intervention strategies down the line. The "Clinical Trial Optional" note indicates that the project may include a clinical trial component if appropriate, but a clinical trial is not required to be responsive.
Eligibility is broad and includes many U.S.-based organizational types that could plausibly operate a multisite clinical research effort. Eligible applicants listed include state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses. The notice also highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, Indian/Native American Tribal Governments other than federally recognized entities, and U.S. territories or possessions. Foreign institutions (non-U.S. entities applying as primary applicants) are not eligible to apply, but non-domestic components of U.S. organizations may participate, and foreign components are allowed as defined by the NIH Grants Policy Statement, which typically means specific international elements can be included when they add unique expertise or resources and are well-justified.
Administratively, the funding instrument is a cooperative agreement, the activity category is health, and the CFDA number provided is 93.310. The FOA was created on August 24, 2018, and the original closing date was October 24, 2018. The listing indicates that only one MCC award is intended ("support one Multisite Clinical Center"), emphasizing that NIH was looking for a single lead center capable of coordinating multisite enrollment and harmonized data collection at scale. The award ceiling and expected number of awards are not specified in the provided text, but the structural design of the FOA strongly suggests a large, centrally coordinated effort with significant operational responsibility for participant recruitment, standardized follow-up, and integrated data capture suited for identifying acute-to-chronic pain biosignatures after musculoskeletal trauma.Apply for RFA RM 18 033
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Multisite Clinical Center Common Fund Acute to Chronic Pain Signatures Program: Acute Pain from Musculoskeletal Trauma (UM1 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.310.
- This funding opportunity was created on 2018-08-24.
- Applicants must submit their applications by 2018-10-24. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the official title and number of this NIH funding opportunity?
The opportunity is NIH RFA-RM-18-033, titled "Multisite Clinical Center Common Fund Acute to Chronic Pain Signatures Program: Acute Pain from Musculoskeletal Trauma (UM1 Clinical Trial Optional)."
What is the main purpose of this grant?
The purpose is to support a single Multisite Clinical Center (MCC) that can recruit and follow a large cohort of patients who have acute pain due to musculoskeletal trauma, then perform multimodal, longitudinal assessments to identify biological signatures (biosignatures) associated with either resilience (recovery without long-term pain) or the transition from acute pain to chronic pain.
What kind of award mechanism is being used?
This is a discretionary federal grant using a cooperative agreement mechanism (UM1). A cooperative agreement typically means the awardee conducts the work in close coordination with NIH program staff rather than operating entirely independently.
What does it mean that this is a cooperative agreement (UM1)?
It means NIH program staff are expected to have substantial involvement, with the awardee coordinating activities and carrying out the project while working closely with NIH on oversight, coordination, and programmatic alignment.
Is a clinical trial required under this FOA?
No. The FOA is labeled "Clinical Trial Optional," which indicates a clinical trial component may be included if appropriate, but a clinical trial is not required to be considered responsive.
What patient population is the MCC expected to enroll?
The MCC is expected to recruit patients who have acute pain resulting from musculoskeletal trauma, and to enroll them soon after the injury in order to follow their recovery or progression over time.
What outcomes or scientific questions is the program trying to address?
The program is aimed at understanding why some individuals recover from acute musculoskeletal trauma pain while others develop persistent (chronic) pain, and at identifying biosignatures linked to resilience or to the acute-to-chronic transition.
What does "multimodal longitudinal assessment" imply for the study design?
It implies the MCC should collect multiple types of data (not just one stream such as surveys) and do so at multiple timepoints over follow-up. The description suggests integrating different categories of measurements to support biosignature discovery in a well-characterized cohort.
What kinds of measurements are implied by the FOA description?
The text indicates the MCC would likely integrate several categories of information collected over time, such as clinical evaluations, patient-reported outcomes, functional measures, and biological or other objective data types intended to support biosignature discovery.
What is meant by "biosignatures" in this context?
In this FOA, biosignatures refer to biological signatures (and related objective data patterns) that can be linked either to resilience (recovery without chronic pain) or to the transition from acute pain to chronic pain after musculoskeletal trauma.
How many awards does NIH intend to make?
The provided information indicates NIH intended to support one Multisite Clinical Center (MCC) award, meaning a single lead center coordinating the multisite effort.
Is the award ceiling or expected funding amount provided?
No. The provided text does not specify an award ceiling or a specific expected funding amount.
What is the activity category for this opportunity?
The activity category is health.
What CFDA number is associated with this opportunity?
The CFDA number provided is 93.310.
When was the FOA created and when did it close?
The FOA was created on August 24, 2018, and the original closing date was October 24, 2018.
Who is eligible to apply?
Eligibility is broad and includes many U.S.-based organization types, including: state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses.
Are any additional applicant categories specifically highlighted as eligible?
Yes. The notice highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); faith-based or community-based organizations; regional organizations; eligible federal agencies; Indian/Native American Tribal Governments other than federally recognized entities; and U.S. territories or possessions.
Can a foreign (non-U.S.) institution apply as the primary applicant?
No. Foreign institutions (non-U.S. entities applying as primary applicants) are not eligible to apply based on the provided information.
Can international components be included in the project?
Yes. The text states that non-domestic components of U.S. organizations may participate, and foreign components are allowed as defined by the NIH Grants Policy Statement, typically when they add unique expertise or resources and are well-justified.
What operational role is the MCC expected to play?
The MCC is expected to function as the central coordinating entity for a multisite effort, with significant responsibility for participant recruitment, standardized follow-up over time, harmonized data collection, and integrated data capture suitable for identifying acute-to-chronic pain biosignatures after musculoskeletal trauma.
Why does the FOA emphasize building a "well-characterized cohort" soon after injury?
Because the scientific aim is to study the transition from acute pain to chronic pain, the project is focused on enrolling participants soon after musculoskeletal trauma and then tracking them longitudinally to observe recovery versus persistence of pain and to link those trajectories to measurable biosignatures.
What is the intended longer-term impact of the work supported by this FOA?
The intended impact is to generate evidence that can support better prediction, prevention, or targeted intervention strategies for preventing or mitigating chronic pain following musculoskeletal trauma, based on identified biosignatures and observed recovery trajectories.
Browse more opportunities from the same category: Health
Next opportunity: National Digital Newspaper Program
Previous opportunity: Lower Mekong Initiative (LMI) Embassy Regional Grants
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA RM 18 033
Applicants also applied for:
Applicants who have applied for this opportunity (RFA RM 18 033) also looked into and applied for these:
| Funding Opportunity |
|---|
| Sustainable Peri-urban Water and Sanitation services Apply for BAA DRC WASH 2018 Funding Number: BAA DRC WASH 2018 Agency: Democratic Republic of the Congo USAID-Kinshasa Category: Health Funding Amount: Case Dependent |
| New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (R01 Clinical Trial Not Allowed) Apply for PA 18 908 Funding Number: PA 18 908 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (R01 (Collab) Clinical Trial Not Allowed) Apply for PA 18 907 Funding Number: PA 18 907 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pre-application for the NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (X02 Clinical Trials Not Allowed) Apply for PAR 18 909 Funding Number: PAR 18 909 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (U01) (Clinical Trial Required) Apply for PAR 18 910 Funding Number: PAR 18 910 Agency: National Institutes of Health Category: Health Funding Amount: $3,000,000 |
| U.S. - India Collaborative Vision Research Program (R01 Clinical Trial Not Allowed) Apply for PAR 18 912 Funding Number: PAR 18 912 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Supplements to Advance Research (STAR) from Projects to Programs (Admin Supp)- Clinical Trial Not Allowed Apply for PA 18 914 Funding Number: PA 18 914 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Screening and Management of Unhealthy Alcohol Use in Primary Care: Dissemination and Implementation of PCOR Evidence (R18) Apply for RFA HS 18 002 Funding Number: RFA HS 18 002 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimers Dementia (R01 Clinical Trial Optional) Apply for RFA MH 19 510 Funding Number: RFA MH 19 510 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Characterization of Mycobacterial Induced Immunity in HIV-infected and Uninfected Individuals (R21 Clinical Trial Not Allowed) Apply for PAR 18 923 Funding Number: PAR 18 923 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimers Dementia (R21 Clinical Trial Optional) Apply for RFA MH 19 511 Funding Number: RFA MH 19 511 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Primary Caregiver Technical Assistance Supplements (PCTAS) (Clinical Trial Optional Admin Supp) Apply for PA 18 926 Funding Number: PA 18 926 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovative Technologies for HIV Behavioral and Social Science Research (R43/R44 Clinical Trial Optional) Apply for PA 18 928 Funding Number: PA 18 928 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovative Technologies for HIV Behavioral and Social Science Research (R41/R42 Clinical Trial Optional) Apply for PA 18 927 Funding Number: PA 18 927 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) (R35 Clinical Trial Not Allowed) Apply for RFA DE 19 005 Funding Number: RFA DE 19 005 Agency: National Institutes of Health Category: Health Funding Amount: $650,000 |
| Research Centers in Minority Institutions (RCMI) (U54)- Clinical Trials Optional Apply for RFA MD 18 012 Funding Number: RFA MD 18 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| High-Priority Areas for Research Leveraging EHR and Large-Scale Data (R01 Clinical Trial Not Allowed) Apply for PAR 18 929 Funding Number: PAR 18 929 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development and Optimization of Tasks and Measures for Functional Domains of Behavior (R01 Clinical Trial Not Allowed) Apply for PAR 18 930 Funding Number: PAR 18 930 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Administrative Supplements to Recover Losses Due to Hurricanes Harvey, Irma, and Maria Under the Bipartisan Budget Act of 2018 Non-Construction (Admin Supp Clinical Trial Optional) Apply for PA 18 936 Funding Number: PA 18 936 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research on Chronic Overlapping Pain Conditions (R21 Clinical Trial Not Allowed) Apply for PA 18 939 Funding Number: PA 18 939 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA RM 18 033", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.